行情

FBIO

FBIO

Fortress Biotech
NASDAQ

实时行情|Nasdaq Last Sale

2.830
-0.150
-5.03%
盘后: 2.890 +0.06 +2.12% 16:59 11/26 EST
开盘
2.910
昨收
2.980
最高
2.980
最低
2.805
成交量
44.79万
成交额
--
52周最高
6.10
52周最低
2.360
市值
2.82亿
市盈率(TTM)
-5.9705
分时
5日
1月
3月
1年
5年
Avenue Therapeutics Announces Exercise and Closing of Underwriter’s Over-Allotment Option
NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (the “Company”) (NASDAQ: ATXI), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that the underwriter of its previously announced ...
GlobeNewswire · 11/17 14:30
Fortress Biotech (FBIO) Reports Q3 Loss, Tops Revenue Estimates
Zacks.com · 11/15 22:25
Fortress Biotech 每股收益下降 0.15 美元,高于收入
Fortress Biotech (NASDAQ:FBIO): Q3 GAAP EPS of -$0.26 misses by $0.15. Revenue of $21.09M (+122.5% Y/Y) beats by $2.03M. Shares +4.17%. Press Release
Seekingalpha · 11/15 21:46
Fortress Biotech Q3 EPS $0.54 Up From $(0.07) YoY, Sales $21.10M Up From $9.21M YoY
Fortress Biotech (NASDAQ:FBIO) reported quarterly earnings of $0.54 per share. This is a 871.43 percent increase over losses of $(0.07) per share from the same period last year. The company reported $21.10 million in
Benzinga · 11/15 21:20
Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ: ATXI)
NEW YORK, NY / ACCESSWIRE / November 12, 2021 / Aegis Capital Corp. acted as Sole Bookrunner on a $2.6 Million Public Offering of Common Stock for Avenue Therapeutics (NASDAQ:ATXI). About Avenue Therapeutics Avenue Therapeutics is a specialty...
AccessWire · 11/12 15:40
Avenue Therapeutics Announces Closing of Public Offering of Common Stock
NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (or the “Company”) (NASDAQ: ATXI), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced the closing of its public offering of 1,946,78...
GlobeNewswire · 11/12 14:20
BRIEF-Mustang Bio Reports Q3 Loss Per Share Of $0.19
reuters.com · 11/12 13:14
Mustang Bio Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
WORCESTER, Mass., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologi...
GlobeNewswire · 11/12 13:05
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解FBIO最新的财务预测,通过FBIO每股收益,每股净资产,每股现金流等数据分析Fortress Biotech近期的经营情况,然后做出明智的投资选择。
分析师评级

6位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

0.00%强力推荐
100.00%买入
0.00%中性
0.00%落后大盘
0.00%卖出
目标价格预测
分析师预测FBIO价格均价为10.17,最高价位24.00,最低价为5.00。
最高24.00
均价10.17
最低5.00
现价2.830
EPS
实际EPS
预期EPS
-0.21-0.16-0.10-0.05
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
机构持股
总机构数: 105
机构持股: 3,143.82万
持股比例: 31.56%
总股本: 9,962.94万
类型机构数股数
增持
28
108.73万
建仓
9
22.26万
减持
22
72.53万
平仓
15
34.30万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
制药
-0.45%
制药与医学研究
+0.44%
高管信息
Chairman/President/Chief Executive Officer/Executive Director
Lindsay Rosenwald
Vice Chairman/Executive Director
Michael Weiss
Vice Chairman/Director
Eric Rowinsky
Chief Financial Officer/Treasurer/Secretary
Robyn Hunter
Senior Vice President
George Avgerinos
Independent Director
Jimmie Harvey
Independent Director
Malcolm Hoenlein
Independent Director
Dov Klein
Independent Director
J. Jay Lobell
Independent Director
Kevin Lorenz
暂无数据
FBIO 简况
Fortress Biotech, Inc. (Fortress) 是一家生物制药公司。该公司收购、开发和商业化新型医药和生物技术产品。Fortress通过Fortress及其子公司开发和商业化产品。Fortress拥有11家运营子公司,开展包括 4个处于商业化阶段的项目和25个处于开发阶段的项目,这些项目主要针对6个治疗领域(免疫肿瘤学、血液学、基因治疗、疼痛管理、罕见疾病和皮肤病学)。除了内部开发项目,Fortress还利用其生物制药专业知识和药物开发能力向Fortress的子公司提供帮助,并提供资金和管理服务。Fortress的子公司包括Aevitas Therapeutics、Avenue Therapeutics、Caelum Biosciences、Cellvation, Inc.、Checkpoint Therapeutics、Cyprium Therapeutics、Helocyte, Inc.、Journey Medical Corporation、Mustang Bio、National Holdings Corp和Tamid Bio, Inc.

微牛提供Fortress Biotech Inc(NASDAQ-FBIO)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的FBIO股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易FBIO股票基本功能。